MENLO PARK, CA, Allay Therapeutics, a clinical-stage biotechnology company, announced the completion of its oversubscribed $60M Series C financing.
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the completion of its oversubscribed $60M Series C financing, led by Arboretum Ventures.
Participating in the round were NEA, Temasek, Pavilion Capital, Brandon Capital Partners, Vertex Growth, Vertex Ventures HC, and WTT Investment Ltd.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
